BioSpace News Archive

Challenge aimed at improving patient outcomes by identifying solutions to reduce time between diagnosis and treatment for lung cancer patients

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today announced that it will advance its program to develop topical roflumilast foam (ARQ-154) as a treatment for seborrheic dermatitis into Phase 3 following an End-of-Phase 2 meeting

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, today announced the pricing of its underwritten public offering of 14.5 million shares of its common stock for gross proceeds of

VECT-HORUS, a biotech company that designs and develops vectors that enable therapeutic molecules or imaging agents to be delivered to key organs, has just closed its Series D fund-raising. The first round, held in September 2020, raised €6.7 million and a second round in December 2020 added €5.3 million from private investors, bringing the total amount raised in these two rounds to €12 million. This second fundin

As the resurgence of COVID-19 activity continues in Canada, we are tracking a range of epidemiological indicators to monitor where the disease is most active, where it is spreading and how it is impacting the health of Canadians and public health, laboratory and healthcare capacity.

- ONCOtherapeutics and Dr. James Berenson published promising new data demonstrating that ruxolitinib (RUX), an oral JAK1/2 inhibitor, with only steroids is well tolerated and shows promising efficacy for treating heavily previously treated MM patients.

Celularity Inc., a clinical stage cell therapeutics company focused on the development of innovative allogeneic placenta-derived cellular therapies, today announced that Robert J. Hariri , M.D., Ph.D., Founder, Chairperson and Chief Executive Officer of Celularity and members of the management team will be participating in a f

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Kelly MacDonald has been appointed Senior Vice President and Chief Financial Officer. Ms. MacDonald will join the company effective March 1, 2021 .

Invitae Corporation announced that it has commenced an underwritten public offering of $400.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses.

QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus QIAstat-Dx and NeuMoDx tests continue to detect all known viral variants extremely effectively